1. The hepatitis C virus infects hepatocytes through complex receptor binding and is then replicated within the cells, forming new virions.
2. Seroconversion can take varying amounts of time, from 23-74 days on average depending on virus genotype and other factors.
3. HCV has high genetic variability due to its high mutation rate during replication, and exists as a distribution of closely related variants called quasispecies. There are 7 major genotypes worldwide.
1. The hepatitis C virus infects hepatocytes through complex receptor binding and is then replicated within the cells, forming new virions.
2. Seroconversion can take varying amounts of time, from 23-74 days on average depending on virus genotype and other factors.
3. HCV has high genetic variability due to its high mutation rate during replication, and exists as a distribution of closely related variants called quasispecies. There are 7 major genotypes worldwide.
1. The hepatitis C virus infects hepatocytes through complex receptor binding and is then replicated within the cells, forming new virions.
2. Seroconversion can take varying amounts of time, from 23-74 days on average depending on virus genotype and other factors.
3. HCV has high genetic variability due to its high mutation rate during replication, and exists as a distribution of closely related variants called quasispecies. There are 7 major genotypes worldwide.
CD 81, receptorul scavenger BI-receptor selectiv pentru HDL colesterol; moleculele de adeziune (DC-SIGN si LSIGN, claudina! si receptorii pentru LDL "li#erarea la polul apical al $epatocitului - continut #ogat LDL- celulele depletate de insulele mem#ranare lipidice sla# productive %n particule virale in&ectante ;incluzii intracitoplasmatice cu aspect spongios' SEROCONVERSIE TARDIVA (ISC (")ID*+L +L ,(+NS-*)I"I. /,L0. 1! zile (23-43 !,156! milion de donatii /I0. 33 zile (5-27 3,826! milion de donatii HCV: 8 !ile " #$%1&' &() *1 +ilion ,e ,onatii /B0. 41 zile (24-74 !1'76! milion de donatii VARIA-ILITATE VIRALA 9(ata mutatiilor !81 per nucleotid per ciclu- ::mutatii puncti&orme 9(ata replicarii. !8 7-; virioni6zi; 9,itruri plasmatice : !85 copii +(N 0/C6ml HVR%secvent. ,e ) co,oni care co,i/ic. partial proteina E /","(<G"NI,+," 0I(+L+ Cvasispecii-S"C0"N,+ C<NS"NS- 3-!8= di&erente 5 genotipuri ma>ore -38-?7= di&erente Selectia mutantelor non-neutraliza#ile @escape mutantsA-C(<NICI)+(" (ein&ectii cu genotipuri distincte-C(<NICI)+(" Trans+itere VHC: 1' 0arenteral : ,rans&uzii 6transplant de la donator in&ectat 9ID* 9/emodializa 9Leziuni accidentale in md spitalicesc6nonspitalicesc - Brevalenta !-3= personal medico-sanitar (C populatia generala ' 0erinatal: ,ransmitere doar de la mame /C0-(N+ pozitive la nastere (ata medie de in&ectie 5= Dai ridicata la coin&ectie cu /I0 (!4= -ara asociere cu mod nastere6alaptare 9Copii in&ectati asimptomatici, evolutie #una, $epatita severa rara 1' Se2ual Eficienta redusa Rar in cupluri monogame MSM Incu3atie +e,ie 4%) sapt "%4 sapt'5 Icter 678' -actori virali. % Inc.rcare viral. % 9enotip - (ezistentE la terapie Factori gazd: -sex, vrst, rasa -Polimorfism IL28B - durata infectiei - rspuns imun etc. omor!iditati: - alcool, droguri, - coinfectii: "#$, #%" - steato&, sidero& - autoimunitate, etc TRATA:ENT: 0E9% I;N<R-V $% $8 s.pt.+=ni, cost estimat 28-?8 888 *SD' INI,I"(" . +(N 0/C detecta#il ; +L, crescut :5 luni; In&lamatie6necroza moderata6&i#roza CC Scopul tratamentului in 'epatita cronica R"Sraspuns virusologic sustinut (R) "# nedetecta!il la * luni de la stoparea tratamentului vindecarea +n ,-./ ca&uri 0(R) nedetecta!il1 +m!un2t23irea 'istologiei 'epatice cu dispari3ia inflama3iei 4i regresia fi!ro&ei5 RIBAVIRINA 877%177 +> ?n pri!e !ilnic %munomodulator Creste rata ,e +utatii VHC %:uta>ene!a letala Accentuea!a apopto!a celulelor in/ectate I;N 0E9%I;N alpha%3 "0E9%Intron@ Scherin>%0lou>h'% 1(# +>*A>corp o ,at. pe s.pt.+=n.( 0E9%I;N alpha%a "0E9ASBS@ Roche'% 187 C> o,at. pe s.pt.+=n.( Antiviral 9I+uno+o,ulator -stimuleazE activitatea citoliticE a lim&ocitelor CD7 -contri#uie la limitarea accesului intralo#ular al lim&ocitelor implicate %n rEspunsul in&lamator' 9cresterea marFerilor de activare a macro&agelor ; 9cresterea activitEtii celulelor NG 0EDICTORI VIRALI NE;AVORA-ILI AI EVOLDTIEI NATDRALE SI AI RAS0DNSDLDI LA TRATA:ENT 9T1 si VL initiala ri,icata 5 /i3ro!a avansata Non%respon,eri pacienti la care nu se atinge viremie nedetecta#ila in nici un moment al tratamentului Reca,ere- +(N 0/C nedetecta#il la s&arsitul terapiei cu pozitivarea viremiei dupa intreruperea tratamentului'
0REDICTORI CELDLARI NE;AVORA-ILI 0ENTRD EVOLDTIA NATDRALA SI RAS0DNSDL LA TRATA:ENT +lele IL37B C6, sau ,6, 9enotip CC IL8- asociat cu RVR5 EVR5 SVR5 e2pressia crescuta a IS9 in tesut hepatic ,"L+B("0I( 0erteH B<C"B("0I( Sunt in$i#itori de proteaza 0/C administrati in com#inatii cu B"G I-N6(B0 G,! 0/C IN-L*"N,+ ,(+,+D"N,*L*I +S*B(+ "0<L*,I"I IN-"C,I"I +C*,". Bacientii cu in&ectie acuta cu 0/C pot vindeca #oala spontan in !8= - 31= din cazuri &ara tratament (seH &eminin, genotipuri 3 si 2, IL37B CC 9,ratamentul cu I-N al&a administrat %n &aza acutI a in&ecJiei scade rata cronicizIrilor la !8= (indi&erent de genotipul viral sau nivelul %ncIrcIrii virale iniJiale 9"voluJia cItre cirozI %n decurs de 38 ani- C1= din cei urmariJi vs 38= din adulJii in&ectaJi cronic cu 0/C 9"&icienta tratamentului cu B"G I-N initiat la 7, !3, sau 38 saptamani dupa primul test pozitiv pentru /C0 (N+ prin BC( si continuat pentru !3 vs 3? saptamini la pacienti cu $epatita C acuta